VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

Matthew J. Ellis, MD, PhD
Published: Thursday, Mar 16, 2017



Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

In metastatic disease, the addition of a CDK4/6 inhibitor has shown a benefit in delaying disease progression in trials. But, Ellis adds, the question that remains is do these drugs—ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib—improve overall survival.

Another question is whether these drugs will improve outcome in early disease. Not all patients benefit from CDK4/6 inhibitors, and other avenues such as neoadjuvant endocrine therapy or genomic models may be more beneficial for that subset.

According to Ellis, current trials are too immature to give definite answers to these questions.

<<< View more from the St. Gallen's Breast Cancer Conference


Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

In metastatic disease, the addition of a CDK4/6 inhibitor has shown a benefit in delaying disease progression in trials. But, Ellis adds, the question that remains is do these drugs—ribociclib (Kisqali), palbociclib (Ibrance), and abemaciclib—improve overall survival.

Another question is whether these drugs will improve outcome in early disease. Not all patients benefit from CDK4/6 inhibitors, and other avenues such as neoadjuvant endocrine therapy or genomic models may be more beneficial for that subset.

According to Ellis, current trials are too immature to give definite answers to these questions.

<<< View more from the St. Gallen's Breast Cancer Conference

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x